Researchers have charted the activity of tens of thousands of genes in mouse immune cells over the course of an infection. The study from the University of Melbourne, Australia, the Wellcome Sanger Institute, and their collaborators created the first full dynamic map of how cells learn to fight microbes and then preserve a memory of this for future infections.
The findings, published in the journal Nature Immunology, could help scientists develop new vaccines and therapeutics for a range of diseases by guiding their research into a particular set of immune cells, known as CD4+ T cells, that are essential for generating immunity.
The international research team studied the CD4+ T cells during an experimental infection of mice with malaria-causing parasites, which invade and multiply inside red blood cells. With the aid of machine learning techniques, the research team combined the gene activity data over four weeks of infection to
LONDON (Reuters) – A major non-profit health emergencies group has set up a global laboratory network to assess data from potential COVID-19 vaccines, allowing scientists and drugmakers to compare them and speed up selection of the most effective shots.
Speaking to Reuters ahead of announcing the labs involved, Melanie Saville, director of vaccine R&D at the Coalition for Epidemic Preparedness Innovations (CEPI), said the idea was to “compare apples with apples” as drugmakers race to develop an effective shot to help control the COVID-19 pandemic.
The centralised network is the first of its kind to be set up in response to a pandemic.
In a network spanning Europe, Asia and North America, the labs will centralise analysis of samples from trials of COVID-19 candidates “as though vaccines are all being tested under one roof”, Saville said, aiming to minimise the risk of variation in results.
AUSTIN, Texas, Sept. 29, 2020 /PRNewswire/ — Jurata Thin Film, a company focused on revolutionizing how biologics are shipped and stored, is bringing to market a new technology that allows biologics and vaccines to be packaged, shipped and stored at room temperature for extended periods of time. The first-of-its-kind technology enables up to 500 doses of vaccine to be placed on a single wafer-thin, 8.5″ x 11″ sheet of film, weighing one-hundredth of a pound (5g).
Known as MSI-TX Thin Film™, the technology represents a fundamental shift in biologic packaging and storage technology that removes the need for specialized storage containers and -80º C (-140º F) freezers that today are required to ship and store biologics.
MSI-TX Thin Film also removes the dependency on mass quantities of glass vials (currently in short supply) and removes virtually all distribution limitations. If the biopharma industry embraces and successfully integrates the